Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

More than 35 million people in the U.S. have chronic kidney disease (CKD), a condition in which the kidneys are damaged and ...

Your kidneys are more important to your health than you may realize. In addition to removing waste from the body, these ...

Climate change is increasing the risk of urological diseases, including cancer and kidney conditions, while urological ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

BUT HE SA Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...